10x Genomics Inc (NASDAQ: TXG) started the day on Thursday, with a price increase of 5.18% at $16.46, before settling in for the price of $15.65 at the close. Taking a more long-term approach, TXG posted a 52-week range of $6.78-$17.70.
The Healthcare sector firm’s twelve-monthly sales growth has been -36.10% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -36.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 65.95%. This publicly-traded company’s shares outstanding now amounts to $116.46 million, simultaneously with a float of $112.19 million. The organization now has a market capitalization sitting at $2.08 billion. At the time of writing, stock’s 50-day Moving Average stood at $13.30, while the 200-day Moving Average is $11.55.
10x Genomics Inc (TXG) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Health Information Services Industry. 10x Genomics Inc’s current insider ownership accounts for 11.35%, in contrast to 96.68% institutional ownership. According to the most recent insider trade that took place on Aug 22 ’25, this organization’s Chief Executive Officer sold 9,348 shares at the rate of 13.79, making the entire transaction reach 128,881 in total value, affecting insider ownership by 945,892. Preceding that transaction, on Aug 22 ’25, Company’s Chief Financial Officer sold 22,315 for 13.79, making the whole transaction’s value amount to 307,657. This particular insider is now the holder of 309,273 in total.
10x Genomics Inc (TXG) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
10x Genomics Inc’s EPS increase for this current 12-month fiscal period is 65.95% and is forecasted to reach -0.95 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 22.86% through the next 5 years, which can be compared against the -36.10% growth it accomplished over the previous five years trading on the market.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Let’s observe the current performance indicators for 10x Genomics Inc (TXG). It’s Quick Ratio in the last reported quarter now stands at 4.06. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.25. Similarly, its price to free cash flow for trailing twelve months is now 28.52.
In the same vein, TXG’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.62, a figure that is expected to reach -0.22 in the next quarter, and analysts are predicting that it will be -0.95 at the market close of one year from today.
Technical Analysis of 10x Genomics Inc (TXG)
If we take a close look at the recent performances of 10x Genomics Inc (NASDAQ: TXG), its last 5-days Average volume was 2.67 million that shows plunge from its year to date volume of 3.23 million. During the previous 9 days, stock’s Stochastic %D was recorded 52.84% While, its Average True Range was 66.23.
Raw Stochastic average of 10x Genomics Inc (TXG) in the period of the previous 100 days is set at 81.04%, which indicates a major rise in contrast to 74.70% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.97 that was higher than 0.75 volatility it exhibited in the past 100-days period.
